Contract Pharma Manufacturing News

  1. Ministerial Visit To Athlone Laboratories: A Vision For The Future Of Critical Medicines In Ireland 3/9/2026

    Athlone Laboratories attracted three of the government’s biggest champions for the Irish pharma sector: Peter Burke, Minister for Enterprise, Tourism and Employment; Rory Mullen, Head of BioPharma and Food at IDA Ireland; and Noeleen Hussey, Regional Manager – West Region, IDA Ireland.

  2. Rapport Therapeutics And Tenacia Biotechnology Announce Strategic Collaboration For The Development And Commercialization Of RAP-219 In Greater China 3/9/2026

    Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”) a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, and Tenacia Biotechnology (Hong Kong) Co., Ltd (“Tenacia”), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including in mainland China, Hong Kong, Macau and Taiwan.

  3. Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For ZYNTEGLO 3/9/2026

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Genetix Biotherapeutics Inc. (Genetix), a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced the extension of their long-term commercial manufacturing agreement. Under the expanded agreement, Lonza will expand manufacturing capacity to support growing demand for Genetix’s ZYNTEGLO, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.

  4. Forma Life Sciences Launches U.S. Based Contract Development And Manufacturing Organization (CDMO) For Oral Solid Dosage Development And Commercial Manufacturing In Irvine, California 3/6/2026

    Forma Life Sciences, Inc. today announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing in the United States.

  5. LOTTE BIOLOGICS Signs Letter Of Intent (LOI) For Strategic Collaboration With U.S.-Based Multinational Company That Has Also Presence And Operation In Japan And Taiwan 3/6/2026

    LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Letter of Intent (LOI) for strategic business collaboration with a multinational biotechnology company headquartered in the United States. 

  6. LOTTE BIOLOGICS Signs Strategic Partnership Agreement With U.S.-Based Asimov 3/6/2026

    LOTTE BIOLOGICS (CEO James Park) on March 13th that it has signed a Memorandum of Understanding (MOU) with Asimov, a company headquartered in Boston, Massachusetts, to collaborate in the Contract Development and Manufacturing Organization (CDMO) business.

  7. Codexis Signs Agreement To Manufacture 50 g siRNA Using Its ECO Synthesis® Manufacturing Platform 3/6/2026

    Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

  8. Upperton Advances Sterile Manufacturing Facility With MHRA Submission 3/5/2026

    The facility, built to the current Eudralex Volume 4 Annex 1 requirements with advanced containment control strategies, is in addition to an existing 50,000 sq. ft development and manufacturing facility in Nottingham, UK, and will support the formulation development and manufacturing of aseptic and terminally sterilised drug products for parenteral, nasal and pulmonary drug delivery.

  9. Codexis Signs Agreement To Manufacture 50 g siRNA Using Its ECO Synthesis® Manufacturing Platform 3/4/2026

    Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

  10. Minaris Launches AgentSCREEN Adventitious Virus Detection By NGS To Simplify Viral Safety Testing For Cell Banks And Cell-Based Samples 3/4/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced the launch of AgentSCREEN Adventitious Virus Detection by Next Generation Sequencing (NGS).